^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BMS-813160
i
Other names: BMS-813160, BMS 813160 , BMS813160
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BMS
Drug class:
CCR5 receptor antagonist, CCR2 receptor antagonist
Related drugs:
9d
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. (clinicaltrials.gov)
P1/2, N=46, Completed, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Completed | N=30 --> 46 | Trial completion date: Dec 2024 --> Sep 2024 | Trial primary completion date: Dec 2024 --> Sep 2024
Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
TNFRSF9 (TNF Receptor Superfamily Member 9)
|
Opdivo (nivolumab) • BMS-813160 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)
4ms
BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (clinicaltrials.gov)
P1/2, N=40, Completed, Washington University School of Medicine | Active, not recruiting --> Completed
Trial completion
|
Opdivo (nivolumab) • gemcitabine • albumin-bound paclitaxel • BMS-813160
7ms
GCO 19-1754: Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
P2, N=48, Completed, Icahn School of Medicine at Mount Sinai | N=36 --> 48 | Trial completion date: Sep 2024 --> Nov 2023 | Active, not recruiting --> Completed
Trial completion • Enrollment change • Trial completion date
|
Opdivo (nivolumab) • BMS-813160 • BMS-986253
10ms
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. (clinicaltrials.gov)
P1/2, N=30, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date • Metastases
|
TNFRSF9 (TNF Receptor Superfamily Member 9)
|
Opdivo (nivolumab) • BMS-813160 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)
1year
Late-breaking abstract
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCR2 (C-C Motif Chemokine Receptor 2)
|
Opdivo (nivolumab) • BMS-813160 • BMS-986253
over1year
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1b/2, N=332, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed
Trial completion • Combination therapy • Metastases
|
Opdivo (nivolumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • irinotecan • leucovorin calcium • BMS-813160
almost2years
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. (clinicaltrials.gov)
P1/2, N=30, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Mar 2023 --> Dec 2023
Trial completion date • Trial primary completion date • Metastases
|
TNFRSF9 (TNF Receptor Superfamily Member 9)
|
Opdivo (nivolumab) • BMS-813160 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)
2years
Nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with or without GVAX for locally advanced pancreatic ductal adenocarcinomas: Results of phase I study. (ASCO-GI 2023)
This open-label, single center two-arm phase I/II trial uses neoadjuvant/adjuvant nivolumab and BMS-813160 +/- GVAX following 8 to 16 doses of FOLFIRINOX and SBRT in patients with newly diagnosed LAPC... We determined that nivolumab 480mg IV q4 weeks, GVAX 5x108 cells intradermal q4 weeks, and BMS-813160 300mg PO BID were the RP2D for the phase 2 portion of this investigation which is ongoing. This combination appears safe and neoadjuvant use does not lead to delay in surgery. Clinical trial information: NCT03767582.
P1 data • Metastases
|
CD8 (cluster of differentiation 8) • TNFRSF9 (TNF Receptor Superfamily Member 9) • CCR2 (C-C Motif Chemokine Receptor 2)
|
Opdivo (nivolumab) • 5-fluorouracil • irinotecan • leucovorin calcium • BMS-813160 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)
2years
Neoadjuvant nivolumab combined with CCR2/5 inhibitor or anti-IL-8 antibody in non-small cell lung cancer and hepatocellular carcinoma (SITC 2022)
Methods This phase IIa multi-cohort, two-stage trial was designed to assess the clinical efficacy of BMS-813160 (CCR2/5 inhibitor) and BMS-986253 (anti-IL8 antibody) in patients with resectable NSCLC and HCC. Deep immune monitoring will be performed using multiplex and single-cell analysis platforms to define the immunodynamic effects of the therapies. Trial Registration NCT04123379
Clinical
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCR2 (C-C Motif Chemokine Receptor 2)
|
Opdivo (nivolumab) • BMS-813160 • BMS-986253
almost3years
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. (clinicaltrials.gov)
P1/2, N=30, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Mar 2023
Trial completion date • Trial primary completion date
|
TNFRSF9 (TNF Receptor Superfamily Member 9)
|
Opdivo (nivolumab) • BMS-813160 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)
Share via
